Clin Exp Otorhinolaryngol.  2020 Feb;13(1):64-68. 10.21053/ceo.2019.00395.

Expression of Serum PTTG1 in Laryngeal Carcinoma and Its Correlation to Prognosis

• Ma K
• Sun X
• Ma L
• Zhang S

• KMID: 2501300
• DOI: http://doi.org/10.21053/ceo.2019.00395

Abstract

Objectives
. The purpose of this study was to investigate serum pituitary tumor transforming gene (PTTG1) expression in laryngeal carcinoma and its relationship with the clinical pathological characteristics and prognosis.
Methods
. Expression of serum PTTG1 was measured by enzyme-linked immunosorbent assay in 110 patients with laryngeal carcinoma and 60 patients with vocal cord polyps. Expression of the serum PTTG1 levels relationship with the clinicopathological characteristics and prognosis were analyzed.
Results
. In laryngeal carcinoma patients’ serum, the PTTG1 median concentration was 141.43 pg/mL (interquartile range [IQR], 111.387 to 160.837 pg/mL), significantly higher than that of the vocal cord polyp group of 94.01 pg/mL (IQR, 81.26 to 108.59 pg/mL), and the difference was statistically significant (z=–6.715, P<0.001). PTTG1 expression with lymph node metastasis, clinical stage, and patients with laryngeal carcinoma was significantly correlated with the tumor differentiation degree (P<0.05). The total survival rate of the PTTG1 high expression group was significantly lower than the low expression group, and the difference of total survival time of the two groups was statistically significant (P<0.001).
Conclusion
. The PTTG1 expression level can be used as an index for evaluating prognosis of laryngeal cancer. High PTTG1 expression is one of the factors of poor prognosis of laryngeal carcinoma patients.

Keyword

Laryngeal Cancer; Serum; Transforming Genes; Prognosis

Figure

• 

  Fig. 1. The serum level of PTTG1 in the laryngeal cancer group and the control group. The median concentration of serum PTTG1 in laryngeal cancer patients was significantly higher than that in the vocal cord polyp group. There was a significant difference (P<0.001).

• 

  Fig. 2. The receiver operating characteristic curve of PTTG1 expression in the serum of laryngeal cancer patients. PTTG1 has high sensitivity and specificity in the serum of laryngeal cancer patients. The sensitivity was 88.5%, the specificity was 85.7%, and the area under the curve was 0.933.

• 

  Fig. 3. The survival curve of PTTG1 patients with high and low expression. Kaplan-Meier analysis of the total survival time of the PTTG1 high-expression group and the low-expression group showed that the total survival time of the PTTG1 high-expression group was significantly lower than that of the low-expression group, and the difference in total survival time between the two groups was significant (P<0.001).

Reference

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; Jan-Feb. 62(1):10–29.

2. Rudolph E, Dyckhoff G, Becher H, Dietz A, Ramroth H. Effects of tumour stage, comorbidity and therapy on survival of laryngeal cancer patients: a systematic review and a meta-analysis. Eur Arch Otorhinolaryngol. 2011; Feb. 268(2):165–79.

3. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; Jan-Feb. 64(1):9–29.

4. Hoffman HT, Porter K, Karnell LH, Cooper JS, Weber RS, Langer CJ, et al. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope. 2006; Sep. 116(9 Pt 2 Suppl 111):1–13.

5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; Jan. 100(1):57–70.

6. Smee RI, De-loyde KJ, Broadley K, Williams JR. Prognostic factors for supraglottic laryngeal carcinoma: importance of the unfit patient. Head Neck. 2013; Jul. 35(7):949–58.

7. Pei L, Melmed S. Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol. 1997; Apr. 11(4):433–41.

8. Li H, Yin C, Zhang B, Sun Y, Shi L, Liu N, et al. PTTG1 promotes migration and invasion of human non-small cell lung cancer cells and is modulated by miR-186. Carcinogenesis. 2013; Sep. 34(9):2145–55.

9. Wierinckx A, Auger C, Devauchelle P, Reynaud A, Chevallier P, Jan M, et al. A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors. Endocr Relat Cancer. 2007; Sep. 14(3):887–900.

10. Xiao JQ, Liu XH, Hou B, Yao Y, Deng K, Feng M, et al. Correlations of pituitary tumor transforming gene expression with human pituitary adenomas: a meta-analysis. PLoS One. 2014; Mar. 9(3):e90396.

11. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010; Jun. 17(6):1471–4.

12. Zou H, McGarry TJ, Bernal T, Kirschner MW. Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science. 1999; Jul. 285(5426):418–22.

13. Ramos-Morales F, Dominguez A, Romero F, Luna R, Multon MC, Pintor-Toro JA, et al. Cell cycle regulated expression and phosphorylation of hpttg proto-oncogene product. Oncogene. 2000; Jan. 19(3):403–9.

14. Tong Y, Tan Y, Zhou C, Melmed S. Pituitary tumor transforming gene interacts with Sp1 to modulate G1/S cell phase transition. Oncogene. 2007; Aug. 26(38):5596–605.

15. Bradshaw C, Kakar SS. Pituitary tumor transforming gene: an important gene in normal cellular functions and tumorigenesis. Histol Histopathol. 2007; Feb. 22(2):219–26.

16. Bernal JA, Roche M, Mendez-Vidal C, Espina A, Tortolero M, Pintor-Toro JA. Proliferative potential after DNA damage and non-homologous end joining are affected by loss of securin. Cell Death Differ. 2008; Jan. 15(1):202–12.

17. McCabe CJ, Gittoes NJ. PTTG: a new pituitary tumour transforming gene. J Endocrinol. 1999; Aug. 162(2):163–6.

18. Zhang X, Horwitz GA, Prezant TR, Valentini A, Nakashima M, Bronstein MD, et al. Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). Mol Endocrinol. 1999; Jan. 13(1):156–66.

19. Pezzani R, Bertazza L, Cavedon E, Censi S, Manso J, Watutantrige-Fernando S, et al. Novel prognostic factors associated with cell cycle control in sporadic medullary thyroid cancer patients. Int J Endocrinol. 2019; Feb. 2019:9421079.